Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
Conditions
Keywords
Phase Ib, BHLRM, VOB560, MIK665, NHL, AML, MM, Bcl2, Mcl1
Brief summary
The purpose of the study was to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death. Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.
Detailed description
This was an open-label, non-randomized multi-center phase Ib dose-escalation study with dose expansion arms in four different patient populations. Patients received VOB560 in combination with MIK665 in a once a week (QW) schedule over 21 days cycle. Less frequent dosing schedules could be explored based on emerging data. Patients were to be treated until disease progression or unacceptable toxicities occurred. The study included a dose escalation part (Part 1) and a dose expansion part (Part 2). The following escalation arms were planned: * Arm A: relapsed/refractory (R/R) NHL and R/R MM * Arm B: R/R AML There were 4 expansion arms planned. However, the expansion part of the study was not initiated.
Interventions
DRUGVOB560
Powder for concentrate for solution for infusion
DRUGMIK665
Concentrate for solution for infusion
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of one of the following hematologic malignancies: * relapsed and/or refractory patients with non-Hodgkin lymphoma with radiographically measurable disease with a clearly demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extra nodal lesion at least 1.0 cm in its largest dimension * relapsed and/or refractory patients with MM treated with at least 2 prior regimens, including an IMiD, a proteasome inhibitor proteasome inhibitor, and anti-CD38 antibody (if available) and not eligible for treatment with other regimens known to provide clinical benefit, as determined by the investigator. * relapsed and/or refractory patients with Acute Myeloid Leukemia (AML), pathologically confirmed diagnosis as defined by the WHO Classification and with ≥ 5% blasts in bone marrow. Following ≥ 1 prior therapies who have relapsed or exhibited refractory disease (primary failure) and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established therapeutic regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded). * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institution's guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study.
Exclusion criteria
1. History of severe hypersensitivity reactions to any ingredient of study treatment and/or their excipients. 2. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment. 3. High-risk patients for Tumor Lysis Syndrome according to Cairo et al 2010 criteria or local guidelines. 4. Impaired cardiac function or clinically significant cardiac disease, or history or current diagnosis of ECG abnormalities indicating significant risk of safety including any of the following: 1. Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker 2. Any history of clinical important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, significant hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age 4. Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment 5. Use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study. 6. Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction \[LVEF\] \<50%) 7. Symptomatic congestive heart failure (New York Heart Association ≥ 3) 8. Findings observed in the baseline cardiac MRI that might reflect an increased risk for cardiac adverse events. 5. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M-CSF), thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior to start of study treatment. If thrombopoietin mimetics or erythroid stimulating agents were initiated more than 2 weeks prior to the first dose of study treatment and the patient is on a stable dose, they can be maintained. 6. For AML patients: Peripheral blast counts \> 25,000 blasts / mm3. Patients can receive hydroxyurea to control the peripheral blast counts as long as hydroxyurea can be stopped at least 24 hours prior to obtaining PD biomarkers at screening/baseline. Hydroxyurea can be restarted after sampling if clinically indicated to control blasts prior to the start of study treatment markers. 7. For patients with R/R NHL and R/R MM: * Absolute Neutrophil count \< 1.0 x 109/L * Platelets count \< 50 x 109/ L * Hemoglobin \< 8 g/dl 8. Autologous stem cell transplant within 3 months before the first dose of study treatment. 9. Patients who have undergone a prior allogeneic stem cell transplant before the first dose of study treatment. 10. History of or current interstitial lung disease or pneumonitis grade ≥ 2. 11. Impaired hepatic and renal function defined as: * Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 x upper limit of normal (ULN) * Bilirubin \>1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin) * Creatinine clearance \<50 mL/min (calculated using Cockroft-Gault formula, or measured). 12. Lipase \>1.5 x ULN or serum amylase \>1.5 x ULN and no history of pancreatitis. 13. Increased cardiac troponin above the manufacturer's 99th percentile upper reference limit for local assay at screening Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of AEs and SAEs, including changes in lab values, vital signs, and ECGs | at month 18 | Month 18 is assumed to be study end |
| Incidence of Dose Limiting Toxicities (DLTs) during the first cycle of treatment with VOB560 and MIK665 in combination | at month 18 | Month 18 is assumed to be study end |
| Frequency of dose interruptions | at month 18 | Month 18 is assumed to be study end |
| Frequency of dose reductions | at month 18 | Month 18 is assumed to be study end |
| Dose intensities | at month 18 | Month 18 is assumed to be study end |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under Curve (AUC) of VOB560 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Maximum Plasma Concentration (Cmax) ok VOB560 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Terminal elimination half-life (T1/2) of VOB560 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Clearance (CL) of VOB560 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Apparent volume of distribution (Vz) of VOB560 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Overall Response Rate (ORR) | at month 18 | Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL |
| Maximum Plasma Concentration (Cmax) ok MIK665 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Terminal elimination half-life (T1/2) of MIK665 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Clearance (CL) of MIK665 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Apparent volume of distribution (Vz) of MIK665 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Area Under Curve (AUC) of MIK665 | At the end of Cycle 6 (each cycle is 21 days) | PK parameter |
| Complete Response (CR) rate (and rate of CR or sCR in R/R MM) | at month 18 | Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL |
| Best Overall Response (BOR) | at month 18 | Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL |
| Duration Of Response (DOR) | at month 18 | Month 18 is assumed to be study end Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL |
| Progression Free Survival (PFS) | at month 18 | Month 18 is assumed to be study end As per European LeukemiaNet (ELN) 2017 for relapse/refractory (R/R) AML As per International Myeloma Working Group (IMWG) 2016 for R/R MM As per Lugano Classification 2014 for R/R NHL |
Countries
Belgium, Finland, Hong Kong, Israel, Italy, Japan, South Korea, Spain, United States
Outcome results
None listed